Mechanical Softness of Cancer Cells Shapes Immune Attack and Therapy

Research by Liu et al. and Lei et al. shows that cancer cells with a soft phenotype resist killing by cytotoxic T lymphocytes (CTLs) and adoptive T-cell therapies. Liu et al. demonstrated that cell softness prevents cytolytic T-cell killing of tumor-repopulating cells, while Zhou et al. reported that softness renders both cytotoxic T lymphocytes and T-leukemic cells resistant to perforin-mediated killing. Conversely, Lei et al. found that cholesterol-depletion-induced stiffening of cancer cells enhances adoptive T-cell immunotherapy. Tello-Lafoz et al. identified biophysical vulnerabilities that cytotoxic lymphocytes exploit, and Basu et al. showed that CTLs use mechanical force to potentiate target cell killing, underscoring the mechanistic link between cell mechanics and immune efficacy.

Nature

The surrounding extracellular matrix (ECM) modulates cancer cell mechanics. Levental et al. reported that matrix cross-linking forces tumor progression by amplifying integrin signaling. Plodinec et al. described a nanomechanical signature distinguishing breast cancer from normal tissue. Tan et al. demonstrated that matrix softness regulates plasticity of tumor-repopulating cells via H3K9 demethylation and Sox2 expression. Fuhs et al. observed that rigid tumors contain soft cancer cells, while Alibert et al. questioned whether cancer cells are universally softer than normal cells. Together, these studies link ECM stiffness, intracellular epigenetic states, and cellular softness to tumor aggressiveness.

Nature

Cappell & Kochenderfer summarized long-term outcomes of CAR-T therapy, noting durable remissions in hematologic malignancies. Brown et al. documented regression of glioblastoma after CAR-T treatment, while Sampson et al. described immunologic escape following EGFRvIII peptide vaccination. Masoumi et al. highlighted challenges and prospects of CAR-T targeting cancer stem cells, and Liu et al. emphasized engineering strategies to improve CAR-T efficacy in solid tumors. Maude et al. reported sustained remissions in leukemia with CAR-T cells, reinforcing the therapeutic promise of mechanistically informed immunotherapy.

Nature

Alibert, Goud, and Manneville raised a methodological critique, asking “Are cancer cells really softer than normal cells?” Their analysis suggests that reported softness may depend on measurement techniques and tumor context, challenging the universality of the softness-resistance paradigm.

Nature

The literature presents divergent observations: some studies identify soft cells within stiff, cross-linked matrices (Fuhs et al.), while others dispute the softness claim (Alibert et al.). Quantitative metrics of cell stiffness (e.g., Young’s modulus) are inconsistently reported, limiting direct comparison. Moreover, translation of mechanical modulation strategies from in vitro models to clinical solid-tumor settings remains insufficiently documented.

Nature

Yoon et al. propose ultrasound-based mechanogenetics to prime tumors for CAR-T therapy. Zhang et al. reported that IL-24 improves CAR-T efficacy by targeting tumor stemness. Gilbert et al. identified extracellular ATP-driven nfP2X7 expression as a survival pathway, while So et al. showed that increased matrix stiffness suppresses ATP-induced Ca²+ influx in breast cancer cells. Emerging delivery platforms—including AAV2 vectors for hepatocellular carcinoma (Meumann et al.), engineered AAV3 vectors with reduced serum reactivity (Ito et al.), and CRISPR-Cas9 lipid nanoparticles (Rosenblum et al.)—offer routes to modulate mechanical and metabolic pathways. Continued investigation of store-operated calcium entry in cancer stem cells (Jardin et al.) may further refine mechanobiology-guided immunotherapies.

Nature